Else Nutrition Holdings Inc.

TSX:BABY Stock Report

Mkt Cap: CA$66.4m

We’ve recently updated our valuation analysis.

Else Nutrition Holdings Valuation

Is BABY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BABY?

Other financial metrics that can be useful for relative valuation.

BABY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.9x
Enterprise Value/EBITDA-2.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BABY's PS Ratio compare to its peers?

The above table shows the PS ratio for BABY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.5x
OGO Organto Foods
1.8xn/aCA$39.5m
FRSH Fresh Factory B.C
1.3xn/aCA$32.1m
VERY Very Good Food
1.2xn/aCA$11.9m
MYLK Planting Hope
5.6xn/aCA$55.9m
BABY Else Nutrition Holdings
9x85.1%CA$66.4m

Price-To-Sales vs Peers: BABY is expensive based on its Price-To-Sales Ratio (9x) compared to the peer average (2.5x).


Price to Earnings Ratio vs Industry

How does BABY's PE Ratio compare vs other companies in the CA Food Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a29.5%
n/an/an/a

Price-To-Sales vs Industry: BABY is expensive based on its Price-To-Sales Ratio (9x) compared to the Canadian Food industry average (1.2x)


Price to Sales Ratio vs Fair Ratio

What is BABY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BABY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9x
Fair PS Ratio8.2x

Price-To-Sales vs Fair Ratio: BABY is expensive based on its Price-To-Sales Ratio (9x) compared to the estimated Fair Price-To-Sales Ratio (8.2x).


Share Price vs Fair Value

What is the Fair Price of BABY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BABY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BABY's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BABY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$0.57
CA$2.75
+382.5%
45.5%CA$4.00CA$1.50n/a2
Jan ’24CA$0.55
CA$2.75
+400.0%
45.5%CA$4.00CA$1.50n/a2
Dec ’23CA$0.53
CA$2.75
+418.9%
45.5%CA$4.00CA$1.50n/a2
Nov ’23CA$0.70
CA$3.00
+328.6%
33.3%CA$4.00CA$2.00n/a2
Oct ’23CA$0.71
CA$3.00
+322.5%
33.3%CA$4.00CA$2.00n/a2
Sep ’23CA$0.83
CA$4.00
+381.9%
50.0%CA$6.00CA$2.00n/a2
Aug ’23CA$0.66
CA$4.00
+506.1%
50.0%CA$6.00CA$2.00n/a2
Jul ’23CA$0.60
CA$4.00
+566.7%
50.0%CA$6.00CA$2.00n/a2
Jun ’23CA$1.35
CA$2.50
+85.2%
0%CA$2.50CA$2.50n/a1
May ’23CA$1.30
CA$3.00
+130.8%
0%CA$3.00CA$3.00n/a1
Apr ’23CA$1.37
CA$3.00
+119.0%
0%CA$3.00CA$3.00n/a1
Mar ’23CA$1.16
CA$4.00
+244.8%
0%CA$4.00CA$4.00n/a1
Feb ’23CA$1.41
CA$4.00
+183.7%
0%CA$4.00CA$4.00n/a1
Jan ’23CA$1.14
CA$4.00
+250.9%
0%CA$4.00CA$4.00CA$0.551
Dec ’22CA$1.70
CA$4.00
+135.3%
0%CA$4.00CA$4.00CA$0.531
Nov ’22CA$1.80
CA$5.75
+219.4%
0%CA$5.75CA$5.75CA$0.701
Oct ’22CA$2.61
CA$5.75
+120.3%
0%CA$5.75CA$5.75CA$0.711
Sep ’22CA$2.85
CA$5.75
+101.8%
0%CA$5.75CA$5.75CA$0.831
Aug ’22CA$2.83
CA$5.75
+103.2%
0%CA$5.75CA$5.75CA$0.661
Jul ’22CA$2.98
CA$5.75
+93.0%
0%CA$5.75CA$5.75CA$0.601
Jun ’22CA$2.38
CA$5.75
+141.6%
0%CA$5.75CA$5.75CA$1.351
May ’22CA$2.70
CA$6.50
+140.7%
0%CA$6.50CA$6.50CA$1.301
Apr ’22CA$3.00
CA$6.50
+116.7%
0%CA$6.50CA$6.50CA$1.371
Mar ’22CA$3.58
CA$6.50
+81.6%
0%CA$6.50CA$6.50CA$1.161
Feb ’22CA$3.30
CA$6.50
+97.0%
0%CA$6.50CA$6.50CA$1.411
Jan ’22CA$3.91
CA$6.50
+66.2%
0%CA$6.50CA$6.50CA$1.141

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies